News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
742,411 Results
Type
Article (43821)
Company Profile (318)
Press Release (698258)
Multimedia
Podcasts (116)
Webinars (19)
Section
Business (210993)
Career Advice (2109)
Deals (36759)
Drug Delivery (124)
Drug Development (83421)
Employer Resources (176)
FDA (16831)
Job Trends (15503)
News (357377)
Policy (34132)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2616)
Accelerated approval (34)
Adcomms (26)
Allergies (151)
Alliances (51584)
ALS (174)
Alzheimer's disease (1699)
Antibody-drug conjugate (ADC) (327)
Approvals (17098)
Artificial intelligence (543)
Autoimmune disease (163)
Automation (42)
Bankruptcy (372)
Best Places to Work (11770)
BIOSECURE Act (21)
Biosimilars (199)
Biotechnology (188)
Bladder cancer (160)
Brain cancer (61)
Breast cancer (655)
Cancer (4937)
Cardiovascular disease (421)
Career advice (1788)
Career pathing (37)
CAR-T (287)
CDC (49)
Celiac Disease (2)
Cell therapy (763)
Cervical cancer (36)
Clinical research (71213)
Collaboration (1776)
Company closure (4)
Compensation (1188)
Complete response letters (65)
COVID-19 (2788)
CRISPR (99)
C-suite (890)
Cystic fibrosis (148)
Data (6345)
Decentralized trials (2)
Denatured (36)
Depression (138)
Diabetes (510)
Diagnostics (6797)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (263)
Drug pricing (202)
Drug shortages (31)
Duchenne muscular dystrophy (236)
Earnings (91994)
Editorial (61)
Employer branding (21)
Employer resources (155)
Events (120370)
Executive appointments (1008)
FDA (20020)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1499)
Gene editing (206)
Generative AI (46)
Gene therapy (617)
GLP-1 (1015)
Government (4810)
Grass and pollen (7)
Guidances (385)
Healthcare (19066)
HIV (62)
Huntington's disease (46)
IgA nephropathy (86)
Immunology and inflammation (266)
Immuno-oncology (61)
Indications (120)
Infectious disease (3066)
Inflammatory bowel disease (202)
Inflation Reduction Act (14)
Influenza (119)
Intellectual property (259)
Interviews (327)
IPO (16921)
IRA (57)
Job creations (4070)
Job search strategy (1498)
JPM (64)
Kidney cancer (16)
Labor market (86)
Layoffs (576)
Leadership (34)
Legal (8425)
Liver cancer (92)
Longevity (16)
Lung cancer (666)
Lymphoma (385)
Machine learning (43)
Management (60)
Manufacturing (837)
MASH (170)
Medical device (13865)
Medtech (13922)
Mergers & acquisitions (20914)
Metabolic disorders (1311)
Multiple sclerosis (164)
NASH (17)
Neurodegenerative disease (328)
Neuropsychiatric disorders (92)
Neuroscience (2975)
Neurotech (1)
NextGen: Class of 2026 (6644)
Non-profit (4563)
Now hiring (68)
Obesity (620)
Opinion (289)
Ovarian cancer (168)
Pain (218)
Pancreatic cancer (232)
Parkinson's disease (286)
Partnered (34)
Patents (515)
Patient recruitment (502)
Peanut (60)
People (60952)
Pharmaceutical (90)
Pharmacy benefit managers (31)
Phase 1 (22105)
Phase 2 (31310)
Phase 3 (23461)
Pipeline (5506)
Policy (303)
Postmarket research (2655)
Preclinical (9390)
Press Release (68)
Prostate cancer (242)
Psychedelics (50)
Radiopharmaceuticals (290)
Rare diseases (880)
Real estate (6306)
Recruiting (72)
Regulatory (25459)
Reports (53)
Research institute (2441)
Resumes & cover letters (361)
Rett syndrome (27)
RNA editing (17)
RSV (81)
Schizophrenia (158)
Series A (246)
Series B (194)
Service/supplier (11)
Sickle cell disease (100)
Special edition (25)
Spinal muscular atrophy (160)
Sponsored (43)
Startups (3766)
State (2)
Stomach cancer (19)
Supply chain (107)
Tariffs (96)
The Weekly (78)
Vaccines (1043)
Venture capital (91)
Weight loss (405)
Women's health (94)
Worklife (18)
Date
Today (30)
Last 7 days (587)
Last 30 days (2276)
Last 365 days (30241)
2026 (4076)
2025 (30679)
2024 (35767)
2023 (40629)
2022 (51798)
2021 (56329)
2020 (54791)
2019 (47397)
2018 (35770)
2017 (33136)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (800)
Alabama (85)
Alaska (7)
Arizona (318)
Arkansas (14)
Asia (42172)
Australia (6754)
California (11471)
Canada (3344)
China (1144)
Colorado (483)
Connecticut (486)
Delaware (345)
Europe (90453)
Florida (1717)
Georgia (361)
Hawaii (3)
Idaho (61)
Illinois (890)
India (73)
Indiana (537)
Iowa (22)
Japan (448)
Kansas (127)
Kentucky (40)
Louisiana (26)
Maine (72)
Maryland (1404)
Massachusetts (8254)
Michigan (330)
Minnesota (635)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (123)
New Hampshire (79)
New Jersey (3049)
New Mexico (29)
New York (3026)
North Carolina (1492)
North Dakota (8)
Northern California (5604)
Ohio (340)
Oklahoma (22)
Oregon (46)
Pennsylvania (2325)
Puerto Rico (24)
Rhode Island (48)
South America (1175)
South Carolina (68)
South Dakota (1)
Southern California (4470)
Tennessee (177)
Texas (1770)
United States (40782)
Utah (343)
Vermont (1)
Virginia (280)
Washington D.C. (81)
Washington State (938)
West Virginia (4)
Wisconsin (117)
Wyoming (2)
742,411 Results for "escient pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Incyte Completes Acquisition of Escient Pharmaceuticals
Incyte (Nasdaq:INCY) today announced that it has completed its acquisition of Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic immune and neuro-immune disorders.
May 30, 2024
·
5 min read
Immunology and inflammation
Incyte’s $750M Escient Bet Flops as Skin Disease Assets Stumble
Incyte’s pipeline updates on Monday bring into question the value of its $750 million Escient acquisition in April 2024—and further erode confidence that the biotech can effectively mitigate the impacts of Jakafi’s loss of exclusivity in the coming years, according to analysts.
November 19, 2024
·
2 min read
·
Tristan Manalac
Deals
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists.
April 23, 2024
·
8 min read
Deals
Incyte Inks $750M Deal to Buy Escient and Skin Disease Drug Candidates
CEO Hervé Hoppenot said Tuesday on an investor call that Escient Pharmaceuticals’ two lead assets “address large populations with a clear medical need” with a potential multibillion-dollar market opportunity.
April 23, 2024
·
2 min read
·
Nick Paul Taylor
Press Releases
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
February 13, 2026
·
12 min read
Press Releases
Aucta Pharmaceuticals, Inc. (“Aucta Pharmaceuticals”) prepares for the launch of PYQUVI™ (deflazacort) oral suspension, the first of a new branded-generic rare disease product line
February 8, 2026
·
7 min read
Biotech Beach
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Chronic Spontaneous Urticaria
Escient Pharmaceuticals announced that the first subject has been dosed in CALM-CSU, a Phase 2 clinical proof-of-concept study of EP262 in subjects with chronic spontaneous urticaria.
October 12, 2023
·
3 min read
Drug Development
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Atopic Dermatitis
Escient Pharmaceuticals, a clinical-stage drug development company advancing novel small molecule therapeutics for systemic neuro-immune disorders, today announced that the first subject has been dosed in EASE, a Phase 2a clinical proof-of-concept study of EP262 in subjects with atopic dermatitis (AD).
November 28, 2023
·
3 min read
Press Releases
60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio
January 16, 2026
·
6 min read
Press Releases
China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering
January 12, 2026
·
3 min read
1 of 74,242
Next
